Short Interest in Avalon GloboCare Corp. (NASDAQ:ALBT) Grows By 64.7%

Avalon GloboCare Corp. (NASDAQ:ALBT) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 137,400 shares, a growth of 64.7% from the March 31st total of 83,400 shares. Approximately 2.8% of the company’s shares are short sold. Based on an average daily trading volume, of 170,800 shares, the short-interest ratio is presently 0.8 days.

Avalon GloboCare Stock Down 2.6 %

ALBT stock opened at $0.27 on Friday. Avalon GloboCare has a 52 week low of $0.25 and a 52 week high of $2.42. The company has a market cap of $3.03 million, a price-to-earnings ratio of -0.17 and a beta of 0.19. The business has a fifty day simple moving average of $0.34 and a 200-day simple moving average of $0.45.

Avalon GloboCare (NASDAQ:ALBT) last announced its quarterly earnings results on Monday, April 15th. The company reported ($0.90) EPS for the quarter. The business had revenue of $0.32 million during the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.